InMed Pharmaceuticals Inc... (INM)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3 |
Market Cap | 2.27M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 230.4 |
PE Ratio (ttm) | 0.01 |
Forward PE | n/a |
Analyst | n/a |
Ask | 3.3 |
Volume | 28,112 |
Avg. Volume (20D) | 496,031 |
Open | 3.13 |
Previous Close | 3.17 |
Day's Range | 3.08 - 3.20 |
52-Week Range | 2.42 - 15.70 |
Beta | undefined |
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it en...
Why Price Moved
News

2 weeks ago · newsfilecorp.com
InMed Pharmaceuticals Announces Granting of Patent for Novel CompoundsMarks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, i...